Ronquest N, Paret K, Mladsi DM, Lee LJ. Exploring the value of country-specific cost-effectiveness models in early stages of drug development. Poster presented at the ISPOR Europe 2023; November 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 supplement):S94. doi: 10.1016/j.jval.2023.09.493
Paret K, Beyhaghi H, Herring W, Rousculp M, Toback S, Mauskopf J. Assessing the cost-effectiveness of the Novavax COVID-19 vaccine as a potential booster vaccine option for adults in the United States. Poster presented at the ISPOR Europe 2022; November 7, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S89. doi: 10.1016/j.jval.2022.09.434
Paret K, Ronquest N, Droege M. Economic modeling considerations for rare neurodegenerative diseases of infancy and early childhood. Poster presented at the ISPOR Europe 2022; November 9, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S171. doi: 10.1016/j.jval.2022.09.830
Ronquest N, Clinkscales M, Paret K. How are United States ICER'S evidence ratings determined?: A systematic review of ICER'S evidence ratings in evidence reports for new drugs in 2020 and 2021. Poster presented at the ISPOR Europe 2022; November 7, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):299-300. doi: 10.1016/j.jval.2022.09.1479